Sulaiman Al Habib 9M 2023 profit rises 26% to SAR 1.52 bln; Q3 at SAR 544.8 mln

29/10/2023 Argaam Exclusive

View other reports

Dr. Sulaiman Al Habib Medical Services Group posted a 26% profit jump in the first nine months of 2023 to SAR 1.52 billion, compared to SAR 1.20 billion in the year-earlier period.

Financials (M)

Item	9m 2022	9m 2023	Change‬
Revenues	6,057.06	7,021.95	15.9 %
Gross Income	2,011.07	2,401.89	19.4 %
Operating Income	1,272.93	1,561.47	22.7 %
Net Income	1,209.26	1,521.00	25.8 %
Average Shares	350.00	350.00	-
EPS (Riyals)	3.46	4.35	25.8 %

The medical services provider reported a 15.93% rise year-on-year (YoY) in revenues to SAR 7.02 billion, on continued growth across the group’s operational segments.

The higher revenues were driven the hospital and pharmacy segments, due to the increase in the number of patients and inpatients occupancy, which in turn boosts the pharmacy segment’s sales, compared to the year-earlier period.

Earnings before interest, taxes, depreciation and amortization (EBITDA) rose to SAR 1.91 billion, implying an increase of 20.37% YoY. EBITDA margin also improved reaching 27.26% compared to 26.26% in the same period of 2022.

The net income margin rose to 21.66% from 19.96% in the first nine months of 2022. The net Income increase was spurred by the revenue growth, due to an increase in the number of patients and inpatient occupancy.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2022	Q3 2023	Change‬
Revenues	2,052.19	2,442.81	19.0 %
Gross Income	681.63	843.43	23.7 %
Operating Income	436.09	552.09	26.6 %
Net Income	420.62	544.77	29.5 %
Average Shares	350.00	350.00	-
EPS (Riyals)	1.20	1.56	29.5 %

Item	Q2 2023	Q3 2023	Change‬
Revenues	2,272.27	2,442.81	7.5 %
Gross Income	774.83	843.43	8.9 %
Operating Income	498.81	552.09	10.7 %
Net Income	486.97	544.77	11.9 %
Average Shares	350.00	350.00	-
EPS (Riyals)	1.39	1.56	11.9 %

In Q3 2023, the net profit climbed 30% to SAR 544.8 million from SAR 420.6 million in Q3 2022.

Revenues jumped 19.03% year-on-year (YoY) to SAR 2.44 billion, on continued growth across the group’s operational segments.

EBITDA rose by 24.46% YoY to SAR 676.05 million. EBITDA margin also increased to 27.68% compared to 26.47% in the same period of 2022.

The net income margin rose to 22.30% from 20.50% on the improved number of patients and inpatient occupancy rates.

On a sequential basis, the bottom line grew by 11.9% from SAR 486.9 million in Q2 2023, thanks to a 7.51% rise in revenues, which were hit during the second quarter due to the holy month of Ramadan and Hajj season.

Shareholders’ equity, after minority interest, reached SAR 6.39 billion as of Sept. 30, 2023, up from SAR 5.71 billion a year earlier.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
Q1 2018	1,169.41	-	361.40	-	221.01	-
Q2 2018	1,068.31	-	290.57	-	153.73	-
Q3 2018	1,145.35	-	354.30	-	215.17	-
Q4 2018	1,204.57	-	355.74	-	211.62	-
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
Q1 2019	1,227.90	5.0 %	404.20	11.8 %	248.18	12.3 %
Q2 2019	1,157.19	8.3 %	334.70	15.2 %	163.58	6.4 %
Q3 2019	1,226.74	7.1 %	348.97	(1.5 %)	192.48	(10.5 %)
Q4 2019	1,404.45	16.6 %	435.67	22.5 %	263.49	24.5 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
Q1 2020	1,343.34	9.4 %	399.85	(1.1 %)	258.61	4.2 %
Q2 2020	1,203.01	4.0 %	359.86	7.5 %	203.31	24.3 %
Q3 2020	1,623.91	32.4 %	558.89	60.2 %	323.89	68.3 %
Q4 2020	1,691.35	20.4 %	545.81	25.3 %	329.05	24.9 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
Q1 2021	1,694.79	26.2 %	549.42	37.4 %	349.63	35.2 %
Q2 2021	1,751.21	45.6 %	551.02	53.1 %	339.73	67.1 %
Q3 2021	1,836.35	13.1 %	586.42	4.9 %	380.54	17.5 %
Q4 2021	1,968.13	16.4 %	643.38	17.9 %	396.25	20.4 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
Q1 2022	1,990.86	17.5 %	658.56	19.9 %	422.09	20.7 %
Q2 2022	2,014.01	15.0 %	670.88	21.8 %	414.75	22.1 %
Q3 2022	2,052.19	11.8 %	681.63	16.2 %	436.09	14.6 %
Q4 2022	2,253.68	14.5 %	737.07	14.6 %	427.56	7.9 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %
Q1 2023	2,306.88	15.9 %	783.64	19.0 %	510.57	21.0 %
Q2 2023	2,272.27	12.8 %	774.83	15.5 %	498.81	20.3 %
Q3 2023	2,442.81	19.0 %	843.43	23.7 %	552.09	26.6 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2013	-	-	-	-	-	-
2014	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
2021	7,250.47	23.7 %	2,330.23	25.0 %	1,466.15	31.5 %
2022	8,310.74	14.6 %	2,748.14	17.9 %	1,700.49	16.0 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
Q1 2018	216.53	-	0.62	-	216.53	0.62
Q2 2018	151.51	-	0.43	-	151.51	0.43
Q3 2018	207.93	-	0.59	-	207.93	0.59
Q4 2018	225.34	-	0.64	-	225.34	0.64
2018	801.31	22.1 %	2.29	-	801.31	2.29
Q1 2019	234.08	8.1 %	0.67	-	234.08	0.67
Q2 2019	167.97	10.9 %	0.48	-	167.97	0.48
Q3 2019	198.00	(4.8 %)	0.57	-	198.00	0.57
Q4 2019	270.18	19.9 %	0.77	-	270.18	0.77
2019	870.23	8.6 %	2.49	-	870.23	2.49
Q1 2020	246.60	5.3 %	0.70	-	246.60	0.70
Q2 2020	192.25	14.5 %	0.55	-	192.25	0.55
Q3 2020	298.80	50.9 %	0.85	-	298.80	0.85
Q4 2020	317.83	17.6 %	0.91	-	317.83	0.91
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
Q1 2021	319.00	29.4 %	0.91	-	319.00	0.91
Q2 2021	325.40	69.3 %	0.93	-	325.40	0.93
Q3 2021	348.62	16.7 %	1.00	-	348.62	1.00
Q4 2021	383.59	20.7 %	1.10	-	383.59	1.10
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
Q1 2022	390.51	22.4 %	1.12	-	390.51	1.12
Q2 2022	398.13	22.4 %	1.14	-	398.13	1.14
Q3 2022	420.62	20.7 %	1.20	-	420.62	1.20
Q4 2022	441.50	15.1 %	1.26	-	441.50	1.26
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72
Q1 2023	489.27	25.3 %	1.40	-	489.27	1.40
Q2 2023	486.97	22.3 %	1.39	-	486.97	1.39
Q3 2023	544.77	29.5 %	1.56	-	544.77	1.56

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2013	-	-	-	-	-	-
2014	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
2018	801.31	22.1 %	2.29	-	801.31	2.29
2019	870.23	8.6 %	2.49	-	870.23	2.49
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
2021	1,376.62	30.4 %	3.93	-	1,376.62	3.93
2022	1,650.75	19.9 %	4.72	-	1,650.75	4.72

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	43.25 %	29.04 %	25.94 %
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	38.80 %	22.35 %	20.75 %
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	28.90 %	19.57 %	14.98 %
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	29.69 %	21.84 %	17.47 %
2018	29.69 %	21.84 %	17.47 %
Q1 2019	30.24 %	22.28 %	17.62 %
Q2 2019	30.60 %	22.42 %	17.64 %
Q3 2019	29.97 %	21.82 %	17.14 %
Q4 2019	30.37 %	22.40 %	17.35 %
2019	30.37 %	22.40 %	17.35 %
Q1 2020	29.60 %	22.52 %	17.20 %
Q2 2020	29.83 %	23.35 %	17.52 %
Q3 2020	31.47 %	24.38 %	18.08 %
Q4 2020	31.81 %	24.44 %	18.01 %
2020	31.81 %	24.44 %	18.01 %
Q1 2021	32.42 %	24.53 %	18.15 %
Q2 2021	32.61 %	24.54 %	18.65 %
Q3 2021	32.02 %	24.56 %	18.80 %
Q4 2021	32.14 %	24.56 %	18.99 %
2021	32.14 %	24.56 %	18.99 %
Q1 2022	32.32 %	24.53 %	19.19 %
Q2 2022	32.77 %	24.65 %	19.47 %
Q3 2022	33.08 %	24.69 %	19.85 %
Q4 2022	33.07 %	24.18 %	19.86 %
2022	33.07 %	24.18 %	19.86 %
Q1 2023	33.31 %	24.34 %	20.28 %
Q2 2023	33.51 %	24.58 %	20.69 %
Q3 2023	33.84 %	24.81 %	21.16 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2013	-	-	-
2014	-	-	-
2015	43.25 %	29.04 %	25.94 %
2016	38.80 %	22.35 %	20.75 %
2017	28.90 %	19.57 %	14.98 %
2018	29.69 %	21.84 %	17.47 %
2019	30.37 %	22.40 %	17.35 %
2020	31.81 %	24.44 %	18.01 %
2021	32.14 %	24.56 %	18.99 %
2022	33.07 %	24.18 %	19.86 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	30.90 %	23.18 %	18.52 %
Q2 2018	27.20 %	19.05 %	14.18 %
Q3 2018	30.93 %	23.14 %	18.15 %
Q4 2018	29.53 %	21.76 %	18.71 %
Q1 2019	32.92 %	24.80 %	19.06 %
Q2 2019	28.92 %	19.88 %	14.52 %
Q3 2019	28.45 %	20.73 %	16.14 %
Q4 2019	31.02 %	23.83 %	19.24 %
Q1 2020	29.77 %	25.06 %	18.36 %
Q2 2020	29.91 %	23.54 %	15.98 %
Q3 2020	34.42 %	24.91 %	18.40 %
Q4 2020	32.27 %	24.14 %	18.79 %
Q1 2021	32.42 %	25.27 %	18.82 %
Q2 2021	31.47 %	23.90 %	18.58 %
Q3 2021	31.93 %	24.92 %	18.98 %
Q4 2021	32.69 %	24.22 %	19.49 %
Q1 2022	33.08 %	25.05 %	19.61 %
Q2 2022	33.31 %	24.45 %	19.77 %
Q3 2022	33.21 %	25.01 %	20.50 %
Q4 2022	32.71 %	22.42 %	19.59 %
Q1 2023	33.97 %	25.51 %	21.21 %
Q2 2023	34.10 %	25.39 %	21.43 %
Q3 2023	34.53 %	25.80 %	22.30 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2014	-	-	-	-
Q2 2014	-	-	-	-
Q3 2014	-	-	-	-
Q4 2014	-	-	-	-
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	350.00	-	-	11.82
Q2 2018	350.00	-	-	12.26
Q3 2018	350.00	-	-	12.86
Q4 2018	350.00	2.29	2.29	12.37
Q1 2019	350.00	2.34	2.34	12.43
Q2 2019	350.00	2.39	2.39	11.79
Q3 2019	350.00	2.36	2.36	12.36
Q4 2019	350.00	2.49	2.49	12.55
Q1 2020	350.00	2.52	2.52	13.25
Q2 2020	350.00	2.59	2.59	13.29
Q3 2020	350.00	2.88	2.88	13.74
Q4 2020	350.00	3.02	3.02	14.03
Q1 2021	350.00	3.22	3.22	14.33
Q2 2021	350.00	3.60	3.60	14.56
Q3 2021	350.00	3.75	3.75	14.86
Q4 2021	350.00	3.93	3.93	15.25
Q1 2022	350.00	4.14	4.14	15.67
Q2 2022	350.00	4.35	4.35	15.98
Q3 2022	350.00	4.55	4.55	16.32
Q4 2022	350.00	4.72	4.72	16.80
Q1 2023	350.00	5.00	5.00	17.31
Q2 2023	350.00	5.25	5.25	17.71
Q3 2023	350.00	5.61	5.61	18.27

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2013	-	-	-	-
2014	-	-	-	-
2015	350.00	3.80	3.80	10.38
2016	350.00	2.89	2.89	12.21
2017	350.00	1.87	1.87	12.34
2018	350.00	2.29	2.29	12.37
2019	350.00	2.49	2.49	12.55
2020	350.00	3.02	3.02	14.03
2021	350.00	3.93	3.93	15.25
2022	350.00	4.72	4.72	16.80

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	21.77	21.77	4.14
Q2 2020	29.06	29.06	5.67
Q3 2020	33.48	33.48	7.01
Q4 2020	36.14	36.14	7.77
Q1 2021	38.48	38.48	8.65
Q2 2021	45.35	45.35	11.22
Q3 2021	46.46	46.46	11.71
Q4 2021	41.04	41.04	10.58
Q1 2022	46.02	46.02	12.15
Q2 2022	44.60	44.60	12.13
Q3 2022	45.70	45.70	12.74
Q4 2022	46.77	46.77	13.13
Q1 2023	58.30	58.30	16.83
Q2 2023	54.49	54.49	16.16
Q3 2023	42.02	42.02	12.90

Period	P/E	Adjusted P/E	Price/book
2013	-	-	-
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	36.14	36.14	7.77
2021	41.04	41.04	10.58
2022	46.77	46.77	13.13

Business Segments (Million)

Compared With The

Period	Hospitals	Pharmacies	Others
Q1 2018	970.00	189.00	10.00
Q2 2018	865.00	174.00	30.00
Q3 2018	908.00	175.00	62.00
Q4 2018	938.00	199.00	68.00
Q1 2019	999.00	208.00	21.00
Q2 2019	916.00	201.00	40.00
Q3 2019	984.00	203.00	40.00
Q4 2019	1,102.00	242.00	60.00
Q1 2020	1,053.00	237.00	53.00
Q2 2020	931.00	209.00	63.00
Q3 2020	1,272.00	261.00	91.00
Q4 2020	1,346.00	294.00	52.00
Q1 2021	1,320.00	313.00	62.00
Q2 2021	1,366.00	315.00	70.00
Q3 2021	1,418.00	338.00	80.00
Q4 2021	1,482.00	389.00	97.00
Q1 2022	1,506.00	417.00	68.00
Q2 2022	1,534.00	407.00	73.00
Q3 2022	1,557.00	408.00	87.00
Q4 2022	1,701.00	492.00	61.00
Q1 2023	1,753.00	491.00	63.00
Q2 2023	1,728.00	484.00	60.00
Q3 2023	1,859.00	485.00	99.00

Period	Hospitals	Pharmacies	Others
2015	4,485.00	598.00	40.00
2016	4,157.00	656.00	55.00
2017	3,671.00	680.00	28.00
2018	3,681.00	737.00	170.00
2019	4,001.00	854.00	161.00
2020	4,602.00	1,001.00	259.00
2021	5,586.00	1,355.00	309.00
2022	6,298.00	1,724.00	289.00

Analysts Estimates (Million)

Item	Q3 2023 (e)	Q3 2023 (a)	Change‬
Average	490.90	544.77	10.97 %

Estimates vs Actual (Million)

Item	Q3 2023 (e)	Q3 2023 (a)	Change
Hermes	520.00	544.77	4.8 %
AlJazira Capital	494.60	544.77	10.1 %
SNB Capital	494.00	544.77	10.3 %
OSOOL AND BAKHEET	493.11	544.77	10.5 %
Riyad Capital	488.00	544.77	11.6 %
Sico	487.00	544.77	11.9 %
U-Capital	480.50	544.77	13.4 %
Al Rajhi Capital	470.00	544.77	15.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	100,310.00
Enterprise Value (EV) (M)	105,278.80
Shares Outstanding ((M))	350.00
EPS ( Riyal) (TTM)	6.36
Book Value (BV) ( Riyal)	19.97
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	46.25
P/E (TTM)	45.05
Price/book	14.35
Return on Average Assets (%) (TTM)	13.0
Return on Average Equity (%) (TTM)	33.3

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Sulaiman Al Habib 9M 2023 profit rises 26% to SAR 1.52 bln; Q3 at SAR 544.8 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2023 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Sulaiman Al Habib 9M 2023 profit rises 26% to SAR 1.52 bln; Q3 at SAR 544.8 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2023

Revenue by Business Segment (Latest) 2023 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)